EUCTR2021-004923-34-DE招募中1 期
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN®-RSV Vaccine in Adults =60 Years of Age
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects =60 years of age.
- •2. Informed Consent signed by the subject.
- •3. Subjects may have one or more chronic medical conditions e.g., mild to moderate underlying illnesses such as chronic cardiac diseases and chronic lung diseases (asthma and chronic obstructive pulmonary disease [COPD]), congestive heart failure (CHF), hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or
- •hypothyroidism, that is clinically stable as assessed by the investigator.
- •4. Absence of known, current, and life-limiting diagnoses that render survival to completion of the protocol unlikely.
- •5. Ability to comply with trial requirements, which necessitates access to transportation to on-site visits, including symptom visits for a nasopharyngeal swab.
- •6. Willingness and ability to utilize an application on a personal device (i.e., smartphone, tablet, etc.) or a provisioned device to record solicited events and record all per protocol required data
- •during the surveillance period.
- •7. For women of childbearing potential (WOCBP), agreement to use an acceptable method of contraception during the trial and a negative urine pregnancy test within 24 hours prior to vaccination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 21600
排除标准
- •1. History of or current clinical manifestation of any serious medical condition that in the opinion of the investigator would compromise the safety of the subject, confound data interpretation, or would limit the subject’s ability to complete
- •2. History of or active autoimmune disease, including diabetes mellitus type I. Vitiligo or hypothyroidism requiring thyroid
- •replacement therapy are not exclusions. Rheumatoid arthritis not requiring immunomodulatory and/or immunosuppressant treatment is not an exclusion.
- •3. Known or suspected impairment of immunologic functions, including chronic inflammatory bowel disorders.
- •4. Clinically significant mental disorder that would prevent patients from giving informed consent and complying with study procedures (e.g., completion of the electronic diary).
- •5. Active or recent (within 6 months before enrollment) history of chronic alcohol abuse.
- •6. History of a serious reaction to any prior vaccination or Guillain-Barré syndrome (GBS) within 6 weeks of any prior influenza immunization.
- •7. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g., tris(hydroxymethyl)-amino methane, chicken embryo fibroblast proteins, gentamycin, ciprofloxacin; this includes:
- •Known allergy to eggs or aminoglycosides.
- •History of anaphylaxis or severe allergic reaction to any
- •8. Any administration or planned administration of:
- •A licensed live or vector-based vaccine within 30 days
- •prior to or after trial vaccine administration.
- •A licensed inactivated or ribonucleic acid (RNA)-based vaccine within 14 days prior to or after trial vaccine administration.
- •9. Previous vaccination with an RSV vaccine, or any planned vaccination with an RSV vaccine other than the trial vaccine.
- •10. Planned chronic, systemic administration (defined as more than 14 days) of >10 mg prednisone (or equivalent)/day or any other systemic use of immune-modifying drugs during a
- •period starting from 3 months prior to first administration of the trial vaccine and ending at the End of Study Visit (EOS).
- •The use of topical, inhaled, ophthalmic and nasal
- •glucocorticoids is permitted.
- •11. Administration or planned administration of immunoglobulins and/or any blood products during a period starting from 3 months prior to first administration of the trial vaccine and
- •during the trial.
- •12. Known uncontrolled coagulation disorder. Anticoagulant treatment under adequate control for cardiovascular prophylaxis or prophylaxis of thromboembolic disease or stroke in the setting of atrial fibrillation are permitted.
- •13. Use of any investigational or non-registered drug or vaccine other than the trial vaccine within 30 days prior to the administration of the trial vaccine, or planned administration of such a drug or vaccine between enrollment in the trial and until 4 weeks after the trial vaccine administration.
- •14. Involvement with this trial as research personnel.
- •15. Planned leave or holiday of 4 consecutive weeks or more during the RSV season covered by the study, that would prohibit the reporting of ARI cases and attendance at symptom visits.
- •16.Pregnancy or breast-feeding
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine in Healthy Adults 65 Years of Age or Older Who Are Naive to 23-Valent Pneumococcal Polysaccharide VaccineEUCTR2007-002326-29-NLWyeth Research Division of Wyeth Pharmaceuticals Inc.1,100
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine in Healthy Adults 65 Years of Age or Older Who Are Naive to 23-Valent Pneumococcal Polysaccharide VaccinePneumococcal infectionMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2007-002326-29-BEWyeth Research Division of Wyeth Pharmaceuticals Inc.
进行中（未招募）
不适用
A Phase 3, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine in Healthy Adults 65 Years of Age or Older Who Are Naive to 23-Valent Pneumococcal Polysaccharide VaccinePneumococcal infectionMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2007-002326-29-HUWyeth Research Division of Wyeth Pharmaceuticals Inc.1,100
进行中（未招募）
不适用
A Phase 3, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine in Healthy Adults 65 Years of Age or Older Who Are Naive to 23-Valent Pneumococcal Polysaccharide VaccinePneumococcal infectionMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2007-002326-29-DEWyeth Research Division of Wyeth Pharmaceuticals Inc.1,100
进行中（未招募）
1 期
A clinical study to determine the efficacy of Uproleselan when given inaddition to anti-cancer drugs in adults with a type of cancer called acutemyeloid leukemiaMedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Acute Myeloid LeukemiaEUCTR2018-001076-38-IEGlycoMimetics, Inc.380